AIToday
AI in HealthcareAI Business & IndustryAI WeeklyPublished: Nov 17, 2026, 22:00 JST

Isomorphic Labs raises $5 billion Series C, 2.4x last round

Send on LINE
Isomorphic Labs raises $5 billion Series C, 2.4x last round

3 Key Points

  1. What happened

    Alphabet's Isomorphic Labs closed a $5 billion Series C co-led by Sequoia Capital and Greenoaks, 2.4x its $2.1 billion May round and about 8x its $600 million March 2025 round.

  2. Why it matters

    The step-up in round size signals that investors are willing to commit more capital to Isomorphic Labs at a larger scale, with Andreessen Horowitz joining as a new backer alongside existing investors.

WHO IT HITSThe funding lands on AI drug discovery teams inside Alphabet and their partners, who may see the IsoDDE platform expand from small molecules into biologics as a result of the new capital.

Not sure about something? Ask the AI

Questions and answers are published on this page.

Summaries like this, every morning.

Context & Analysis

Isomorphic Labs' latest round represents a sharp escalation in the capital committed to its AI-driven drug discovery work. The $5 billion Series C is 2.4x the $2.1 billion raised in May and roughly 8x the $600 million round from March 2025, suggesting that existing and new investors are willing to scale up their backing quickly. Sequoia Capital and Greenoaks co-led the round, with Andreessen Horowitz joining as a new investor alongside Thrive Capital, GV, CapitalG, Temasek, MGX and the UK Sovereign AI Fund.

CEO Demis Hassabis framed the funding as a way to accelerate the IsoDDE platform's expansion from small molecules into biologics, a move that would broaden the types of medicines the platform can address. He also said the capital pushes the company toward its first clinical trial submissions in 2027, marking a concrete milestone for a company that has not yet brought a drug to trial. The participation of sovereign and corporate investors alongside venture firms indicates a broad appetite for AI-native drug discovery, though the path to clinical validation remains ahead.

FAQ
Who led Isomorphic Labs' Series C?
Sequoia Capital and Greenoaks co-led the $5 billion round, with Andreessen Horowitz joining as a new investor.
How does this round compare with previous funding?
It is 2.4x the $2.1 billion May round and about 8x the $600 million March 2025 round.
What will the new funding be used for?
CEO Demis Hassabis said it accelerates the IsoDDE platform's expansion from small molecules into biologics and pushes the company toward first clinical trial submissions in 2027.
Send on LINE

Also reported by SiliconANGLE AI, THE DECODER, TechCrunch AI, Top Companies AI

AI news that matters for your work, delivered every morning.

Pick your industry and the AI tools you use, and get news related to your work every day.

Free · 30 seconds with Google · unsubscribe anytimeWhat is AIToday? →

Ask AI

Ask AI anything about this article. The AI reads this article, earlier AIToday articles, and Wikipedia, and cites its sources. Q&As are published on this page for other readers too.

Questions and answers are published on this page.

Related Articles

Next articleShake rolls out AIShaker one-day AI setup for SMEs